Center for Gene and Cell Therapy Co-founded by Miltenyi and ATLATL in Shanghai

March 20, 2019 Off By BusinessWire

SHANGHAI–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Shanghai?src=hash" target="_blank"gt;#Shanghailt;/agt;–To accelerate the development of cell and gene therapy, ATLATL Center
and Miltenyi Biotec have cooperated to build ATLATL-MACS Center for Gene
and Cell Therapy. Miltenyi is a global leader in the design,
development, manufacturing, and integration of products that empower the
advancement of biomedical research and enable cutting-edge cell and gene
therapies. Miltenyi provides a robust innovative portfolio of cellular
technologies used seamlessly in a variety of research, translational,
and clinical applications.

ATLATL has the world’s largest shared Class-A level laboratory space,
designed as a launchpad for high-potential life sciences. It offers
fully permitted laboratories and office space for scientists and
entrepreneurs. To meet the demands of growing research teams, ATLATL
provides full service state-of-the-art facilities, the most advanced
instruments, professional operations support, skilled laboratory
personnel, on-site CROs, and the most creative Module research services,
serving teams of various size who need to begin immediate laboratory
operations. The Center is approximately 25,000 square feet, functions as
a talent training center, expedites process development, and cell and
gene therapy platforms. The center includes specialized laboratories for
cell collection, separation, production, microscopic imaging, and
storage and transportation.

In recent years, advances in gene editing technology and viral vectors,
gene and cell therapy has developed from theory to reality with major
breakthroughs, as a promising emerging sector in medicine. Companies
engaged in this field are sought in capital markets, and a large number
of companies have completed IPO listings, including Bluebird Bio,
Celladon, Orchard, and Spark. Many gene and cell therapies have
demonstrated impressive results in clinical trials and more treatments
could be approved in coming years.

ATLATL and Miltenyi spent nearly one year on planning and construction,
finally built the ATLATL-MACS Center in March 2019 with a specialized
focus to remove hurdles encountered in current treatments. The Center
offers a complete research and development platform and will actively
train researchers, work with more R&D teams to conduct new process
development and application discovery, establish complete standardized
operating procedures, assist pharmaceutical companies conduct accurate
disease diagnosis and efficacy evaluations, accelerating clinical
transformation and commercialization of gene and cell therapy.

The ATLATL-MACS Center covers the biomedical industry chain and will
gather a series of innovative teams, which have important strategic
significance for the development of local life sciences. The center will
provide services to biological companies through more than 10 million
euro cutting-edge instruments and expert team. Miltenyi’s
CliniMACSProdigy is the unique automated CAR-T preparation instrument,
greatly speeding up the cell therapy and development in clinical
applications. The Center will lower the gene and cell therapy industry
innovation threshold locally and globally.

Miltenyi Biotec has previously collaborated with many giant
pharmaceuticals, such as GlaxoSmithKline (GSK) on the
“industrialization” of cell and gene therapy. Differently, the
cooperation between Miltenyi and ATLATL is an open platform to biotech
companies. The center will help biopharmaceutical companies and
scientific research institutions integrate R&D, training,
commercialization. It will greatly reduce the initial cost in research
and development and help companies accelerate the clinical
transformation and commercialization of cell and gene therapy to benefit
more patients.

{ATLATL Center is a component of ATLATL Innovation Cluster (AIC), which
is an ecosystem with educational and research centers, on-site CROs,
entrepreneurship, venture capital, and life sciences companies. AIC
strives to increase research density and accelerate research
commercialization. Innovative teams can jumpstart with turnkey
solutions, leverage resources more efficiently, and reach milestones
faster than ever.}